Phathom Pharmaceuticals Inc (PHAT)
12.32
+6.12%
Phathom Pharmaceuticals Inc (PHAT) is currently trading at $12.32. This represents a gain of 6.12% from the previous session. With a market capitalization of $0.96B, PHAT is a key component of the Health Care sector. Investors looking to trade PHAT should compare margin rates and options platforms to optimize their portfolio management.
Broker Promotion
Claim Your $300 Cash Bonus →
T&Cs Apply. Trade PHAT commission-free.
Trading Platform Comparison
Moomoo
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Good for small traders
IBKR
- Min Deposit: $0
- Commissions: $0–$0.005/share
- Fractional Shares: ✅
- Options: ✅
- Notes: Professional-level tools
Ameritrade
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Strong research tools
Webull
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Easy mobile app
AI Market Sentiment
As of today, Phathom Pharmaceuticals Inc (PHAT) shows a bullish trend. Analysts are watching the 12.65 level closely.
Fundamentals
Mkt Cap0.96B
P/E Ratio0.0000
Volume1,721,238
60-Day Technical Chart
Advanced Charting
Need more indicators for PHAT? Use the world's #1 platform.
Open PHAT on TradingView →Charting Platforms
TradingView
Advanced charts & indicators, web & mobile
StockCharts
Technical analysis charts with overlays & indicators
BarCharts
Market data, charts, and technical signals
Finviz
Visual stock charts & heatmaps
Yahoo Finance Charts
Basic interactive charts with indicators
Side-by-Side: Stocks Near $12
| Metric |
PHAT +6.12% |
OWL +5.78% |
AAL +1.29% |
SMR -1.86% |
|---|---|---|---|---|
| Price | $12.32 | $11.35 | $13.32 | $13.18 |
| Mkt Cap | $0.96B | $17.54B | $8.81B | $4.01B |
| - | View → | View → | View → |
Latest Headlines
Biotech Phathom heads to Boston and Miami for investor talks in March
Stock Titan • Feb 23, 2026
Phathom Pharmaceuticals to Report Fourth Quarter and Full
GlobeNewswire • Feb 17, 2026
With 51% ownership of the shares, Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) is heavily dominated by institutional owners
Yahoo Finance • Oct 28, 2025
Phathom Pharmaceuticals Stock (PHAT) Opinions on Phase 3 VOQUEZNA Study Results
Quiver Quantitative • Oct 26, 2025
Phathom Pharmaceuticals (NASDAQ:PHAT investor five-year losses grow to 69% as the stock sheds US$66m this past week
simplywall.st • Sep 16, 2025
● Gemini Agentic AI Analyst Insight for PHAT
Market Education
- I don't get this Dollar Cost Averaging (DCA). Explain pls Jul 18, 2023
- Understanding Hedge Fund Alpha and Beta: A Guide for New Investors Jun 2, 2024
- Government Shutdowns: What They Mean for Wall Street Sep 26, 2025
External Research